This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by PD-1/PD-L1 maintenance therapy
Age between18 years and 80 years at time of study entry
ECOG performance status of 0 or 1
Body weight >30 kg
Adequate bone marrow, liver and kidney function
Previous chemo-, immuno- or radiotherapy for SCLC
Major surgical procedure last 28 days
History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or HIV
Uncontrolled intercurrent illness